Bioline Rx Ltd - ADR (BLRX) Company Profile & Statistics

Bioline Rx Ltd - ADR
BLRX
(Nasdaq - US)
N/A
0.65
+0.03 (+4.50%)
in:usd•As of: May 14, 2024 15:46 UTC -4
Open
0.63
High
0.65
Low
0.63

About Bioline Rx Ltd - ADR

CEO

Philip A. Serlin

Headquarters

2 hama-ayan street, modi-in technology park

modi-in, l3 7177871, israel

Auditor

Kesselman & Kesselman

Employees

Share Holders

N/A

Website

www.biolinerx.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases.

Bioline Rx Ltd - ADR Statistics

Valuation Measures

Market Capitalization ²	51.96M
Enterprise Value	57.48M
Enterprise Value/EBITDA (ttm)	-1.08
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	3.57
Price to Sales (ttm)	N/A
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	0.00%
Operating Margin (ttm)	N/A
Profit Margin (ttm)	0.00%
Return on Equity (ttm)	-280.21%
Return on Invested Capital (ttm)	-232.59%
Return on Assets (ttm)	-99.22%

Income Statement

Revenue (ttm)	0.00
Revenue Per Share (ttm)	0.00
Gross Profit (ttm)	0.00
EBITDA (ttm)³	-53.11M
Net Income Avi to Common (ttm)	-60.61M
Diluted EPS (ttm)	-0.90

Share Statistics

Beta (5Y Monthly)	1.50
52-Week Change	-52.90%
S&P500 52-Week Change	26.85%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	72.44M
Dividend Yield	0.00%
Float ⁴	79.06M
% Held by Insiders	1.10%
% Held by Institutions	1.56%

Balance Sheet

Total Cash (mrq)	42.99M
Total Cash Per Share (mrq)	0.59
Total Debt (mrq)	9.77M
Total Debt/Equity (mrq)	73.91%
Current Ratio (mrq)	1.53%
Quick Ratio (mrq)	1.47%
Book Value Per Share (mrq)	0.18

Cash Flow

Operating Cash Flow Per Share (ytd)	-0.35
Free Cash Flow (ytd)	-22.72M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Bioline Rx Ltd - ADR

Trade With A Regulated Broker